Document is current

Article History

Accepted: 8 May 2023

First Online: 31 May 2023

Declarations

:

: No external funding was used in the preparation of this manuscript.

: The authors whose names are listed immediately below report the following details of affiliation or involvement in an organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this manuscript. Avani M Singh, Jose A Guevara-Patino, and Xuefeng Wang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Roger Li: Research Support: Predicine; Veracyte; CG Oncology; Valar labs. Clinical Trial Protocol Committee: CG Oncology. Scientific Advisor/Consultant: BMS, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence. Honoraria: SAI MedPartners, Solstice Health Communications, UroToday. Guru Sonpavde: Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV, Vial. Consultant/scientific advisory board (SAB): Suba Therapeutics. Research support to institution: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric. Speaker and travel costs: BIO—INFORMAÇÃO BRASILEIRA DE ONCOLOGIA Ltda. Data safety monitoring committee honorarium: Mereo. Employment: Spouse employed by Myriad. Rohit K Jain: Advisory Board: BMS, EMD Serono, Seattle Genetics/Astellas, Gilead. Consultant/scientific review committee member: NCCN. Research support to institution: Gilead, BMS. Speaker bureau: Seattle Genetics, Gilead. Honorarium: Dava Oncology

: Not applicable

: No datasets were generated or analyzed during the current study.

: Not applicable.

: AMS and RKJ contributed equally to the writing of the manuscript. JAG-P, XW, RL, and GS each provided feedback on the manuscript.